To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks observations.
The purpose of our study was to evaluate the diagnostic ability of CEUS with perflubutane to identify HCC on the indeterminate observation in Gd-EOB-MRI and to establish the role of CEUS as a second-line (post-Gd-EOB-MRI) modality for HCC diagnosis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
120
Perflubutane enhanced ultrasound for evaluating hepatic tumor
Seoul National University Hospital
Seoul, South Korea
RECRUITINGCompared the image features of CEUS and Gd-EOB-MRI in at-risk observation
Compared the frequency of arterial phase hyperenhancement (APHE) and washout in at-risk observation, between CEUS and Gd-EOB-MRI.
Time frame: 1. For 3 days after undergoing CEUS to check the complication of CEUS, per each participants. 2. The time interval between CEUS and Gd-EOB-MRI should not be exceed 4 weeks.
Compared diagnostic performance of Gd-EOB-MRI alone and Gd-EOB-MRI with CEUS.
Evaluated sensitivity, specificity and accuracy for diagnose HCC by using Gd-EOB-MRI alone, or Gd-EOB-MRI with CEUS.
Time frame: 1. For 3 days after undergoing CEUS to check the complication of CEUS, per each participants. 2. The time interval between CEUS and Gd-EOB-MRI should not be exceed 4 weeks.
Comparing image characters between two types of ultrasound contrast media
Comparing image characters between two types of ultrasound contrast media
Time frame: For 3 days after undergoing CEUS to check the complication of CEUS, per each participants.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.